Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone versus sertraline versus PPI for functional dyspepsia with anxiety symptoms
IRCT20210831052349N1Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of buspirone and sertraline in functional dyspepsia (FD) and anxiety disorder (3 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoints: Anxiety and Clinical gastrointestinal symptoms. Started Nov 2021; status: completed.
02
Drugs
buspironesertraline
03
Conditions
functional dyspepsia (FD)anxiety disorder
Beyond the preview
Go deeper on IRCT20210831052349N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210831052349N1.